

**TABLE 1.** Cardiovascular and renal outcomes of GLP-1 receptor agonists

	<b>ELIXA</b>	<b>LEADER</b>	<b>EXSCEL</b>	<b>SUSTAIN 6</b>	<b>REWIND</b>	<b>HARMONY</b>
Patients with established cv disease	100%	81%	73%	83%	31.5%	100%
CV outcomes						
MACE-3	-	0.87 (0.78 – 0.97)	0.91 (0.83 - 1.00)	0.74 (0.58 – 0.95)	0.88 (0.79-0.99)	0.78 (0.68–0.90)
CV death	0.98 (0.78 – 1.22)	0.78 (0.66 – 0.93)	0.88 (0.76 – 1.02)	0.98 (0.65 – 1.48)	0.91 (0.78-1.06)	0.93 (0.73–1.19)
Non-fatal MI	-	0.88 (0.75 – 1.03)	0.97 (0.8 – 1.10)	0.74 (0.51-1.08)	0.96 (0.79–1.16)	0.75 (0.61–0.90)
Non-fatal stroke	-	0.89 (0.72 – 1.11)	0.85 (0.70 – 1.03)	0.61 (0.38 – 0.99)	0.76 (0.61–0.95)	0.86 (0.66–1.14)
Mortality	0.94 (0.78 – 1.13)	0.85 (0.74 – 0.97)	0.86 (0.77 – 0.97)	1.05 (0.74 – 1.50)	0.90 (0.80–1.01)	0.95 (0.79–1.16)
HF hospitalization	0.96 (0.75 – 1.23)	0.87 (0.73 – 1.05)	0.94 (0.78 – 1.13)	1.11 (0.77 – 1.61)	0.93 (0.77–1.12)	-
Renal outcomes						
Composite renal outcome	-	0.78 (0.67 – 0.92)	0.88 (0.74 - 1.05)	0.64 (0.46 – 0.88)	0.85 (0.77–0.93)	-

\*Data are presented as hazard ratio, 95% confidence intervals

Abbreviations: CV: cardiovascular, MACE: major adverse cardiovascular events, MI: myocardial infraction, HF: heart failure